324 related articles for article (PubMed ID: 8195463)
1. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.
Preskorn SH; Alderman J; Chung M; Harrison W; Messig M; Harris S
J Clin Psychopharmacol; 1994 Apr; 14(2):90-8. PubMed ID: 8195463
[TBL] [Abstract][Full Text] [Related]
2. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
Alderman J; Preskorn SH; Greenblatt DJ; Harrison W; Penenberg D; Allison J; Chung M
J Clin Psychopharmacol; 1997 Aug; 17(4):284-91. PubMed ID: 9241008
[TBL] [Abstract][Full Text] [Related]
3. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic interchange of fluoxetine and sertraline: experience in the clinical setting.
Stock AJ; Kofoed L
Am J Hosp Pharm; 1994 Sep; 51(18):2279-81. PubMed ID: 7801990
[No Abstract] [Full Text] [Related]
5. The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Kurtz DL; Bergstrom RF; Goldberg MJ; Cerimele BJ
Clin Pharmacol Ther; 1997 Aug; 62(2):145-56. PubMed ID: 9284850
[TBL] [Abstract][Full Text] [Related]
6. An interaction of sertraline and desipramine.
Barros J; Asnis G
Am J Psychiatry; 1993 Nov; 150(11):1751. PubMed ID: 8214190
[No Abstract] [Full Text] [Related]
7. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
Ereshefsky L; Riesenman C; Lam YW
Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
[TBL] [Abstract][Full Text] [Related]
8. Drug-drug interactions.
Preskorn SH
J Clin Psychiatry; 1996 May; 57(5):223-7. PubMed ID: 8626354
[No Abstract] [Full Text] [Related]
9. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin.
Hamelin BA; Turgeon J; Vallée F; Bélanger PM; Paquet F; LeBel M
Clin Pharmacol Ther; 1996 Nov; 60(5):512-21. PubMed ID: 8941024
[TBL] [Abstract][Full Text] [Related]
10. Interactions between sertraline and tricyclic antidepressants.
Lydiard RB; Anton RF; Cunningham T
Am J Psychiatry; 1993 Jul; 150(7):1125-6. PubMed ID: 8317590
[No Abstract] [Full Text] [Related]
11. [New antidepressive agents].
LaBranche S
Union Med Can; 1995 Nov; 124(3):8-13. PubMed ID: 8560639
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of the newer antidepressants.
Burke MJ; Harvey AT; Preskorn SH
Am J Med; 1996 Jan; 100(1):119-21. PubMed ID: 8579077
[No Abstract] [Full Text] [Related]
13. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline.
Preskorn S
Int Clin Psychopharmacol; 1994 Jun; 9 Suppl 3():13-9. PubMed ID: 7963446
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
Baumann P
Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
[TBL] [Abstract][Full Text] [Related]
15. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
Preskorn SH
Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
[TBL] [Abstract][Full Text] [Related]
16. Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline.
Kanekar S; Sheth CS; Ombach HJ; Olson PR; Bogdanova OV; Petersen M; Renshaw CE; Sung YH; D'Anci KE; Renshaw PF
Pharmacol Biochem Behav; 2018 Jul; 170():25-35. PubMed ID: 29738811
[TBL] [Abstract][Full Text] [Related]
17. Sertraline: a new antidepressant.
Auster R
Am Fam Physician; 1993 Aug; 48(2):311-4. PubMed ID: 8342482
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo.
von Moltke LL; Greenblatt DJ; Cotreau-Bibbo MM; Duan SX; Harmatz JS; Shader RI
J Pharmacol Exp Ther; 1994 Mar; 268(3):1278-83. PubMed ID: 8138941
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression.
Miller HL; Delgado PL; Salomon RM; Berman R; Krystal JH; Heninger GR; Charney DS
Arch Gen Psychiatry; 1996 Feb; 53(2):117-28. PubMed ID: 8629887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
